Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

[Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].

Xu C, Liu YL, Huang J, He DM, Hou YY, Ji Y, Hou J, Lu SH, Xu JF, Hu Q, Shi Y, Zhao LJ, Tan YS.

Zhonghua Bing Li Xue Za Zhi. 2012 Oct;41(10):667-70. doi: 10.3760/cma.j.issn.0529-5807.2012.10.005. Chinese.

PMID:
23302307
2.
3.
4.

Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.

Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS.

J Pathol. 2009 Dec;219(4):435-45. doi: 10.1002/path.2625.

PMID:
19824059
5.

Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer.

Bennani B, Gilles S, Fina F, Nanni I, Ibrahimi SA, Riffi AA, Nejjari C, Benajeh DA, El Abkari M, Martin PM, Ouafik L.

Int J Biol Markers. 2010 Oct-Dec;25(4):179-84.

PMID:
21161938
6.

[Correlation of KRAS gene mutations and clinicopathologic parameters in colorectal carcinoma].

Wang Q, Zhong M, Lü YL, Yuan J, Wei LX.

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):603-6. doi: 10.3760/cma.j.issn.0529-5807.2012.09.007. Chinese.

PMID:
23157828
7.

[Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].

Gao J, Zhang J, Lu T, Li XY, Jia N, Liang ZY.

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):595-8. doi: 10.3760/cma.j.issn.0529-5807.2012.09.005. Chinese.

PMID:
23157826
8.
9.

[KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese].

Zhu XL, Cai X, Zhang L, Yang F, Sheng WQ, Lu YM, Du X, Zhou XY.

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):584-9. doi: 10.3760/cma.j.issn.0529-5807.2012.09.003. Chinese.

PMID:
23157824
10.
11.

KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.

Lewandowska MA, Jóźwicki W, Żurawski B.

Mol Diagn Ther. 2013 Jun;17(3):193-203. doi: 10.1007/s40291-013-0025-8.

12.

KRAS mutations in colorectal cancer from Tunisia: relationships with clinicopathologic variables and data on TP53 mutations and microsatellite instability.

Aissi S, Buisine MP, Zerimech F, Kourda N, Moussa A, Manai M, Porchet N.

Mol Biol Rep. 2013 Nov;40(11):6107-12.

PMID:
24078161
13.

Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas.

Harlé A, Busser B, Rouyer M, Harter V, Genin P, Leroux A, Merlin JL.

Virchows Arch. 2013 Mar;462(3):329-35. doi: 10.1007/s00428-013-1380-x.

PMID:
23400679
14.

[Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].

Ling Y, Ying JM, Qiu T, Shan L, Guo L, Lü N.

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):590-4. doi: 10.3760/cma.j.issn.0529-5807.2012.09.004. Chinese.

PMID:
23157825
15.

[Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].

Gao J, Sun ZW, Li YY, Shen L.

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):579-83. doi: 10.3760/cma.j.issn.0529-5807.2012.09.002. Chinese.

PMID:
23157823
16.

Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population.

Sinha R, Hussain S, Mehrotra R, Kumar RS, Kumar K, Pande P, Doval DC, Basir SF, Bharadwaj M.

PLoS One. 2013;8(4):e60142. doi: 10.1371/journal.pone.0060142.

17.

Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?

Koçer NE, Kayaselçuk F.

Target Oncol. 2014 Jun;9(2):171-5. doi: 10.1007/s11523-013-0275-8.

PMID:
23588415
18.

Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study.

Dinu D, Dobre M, Panaitescu E, Bîrlă R, Iosif C, Hoara P, Caragui A, Boeriu M, Constantinoiu S, Ardeleanu C.

J Med Life. 2014 Oct-Dec;7(4):581-7.

19.

KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.

Sundström M, Edlund K, Lindell M, Glimelius B, Birgisson H, Micke P, Botling J.

BMC Cancer. 2010 Dec 1;10:660. doi: 10.1186/1471-2407-10-660.

20.

KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients.

Gil Ferreira C, Aran V, Zalcberg-Renault I, Victorino AP, Salem JH, Bonamino MH, Vieira FM, Zalis M.

BMC Gastroenterol. 2014 Apr 10;14:73. doi: 10.1186/1471-230X-14-73.

Supplemental Content

Support Center